Mast Therapeutics Inc (NASDAQ:MSTX) had its price target upped by equities researchers at S&P Equity Research from $0.08 to $0.09 in a research note issued to investors on Friday. S&P Equity Research’s price target suggests a potential upside of 5.88% from the company’s current price.
A number of other research firms also recently issued reports on MSTX. Maxim Group set a $5.00 price target on shares of Mast Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 8th. Laidlaw downgraded shares of Mast Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 21st. Zacks Investment Research downgraded shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Roth Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Mast Therapeutics in a research note on Friday, July 15th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $3.00 price target on shares of Mast Therapeutics in a research note on Thursday, July 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $2.07.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.085 on Friday. Mast Therapeutics has a 12 month low of $0.08 and a 12 month high of $0.71. The stock’s market capitalization is $18.00 million. The company’s 50-day moving average is $0.31 and its 200-day moving average is $0.36.
Mast Therapeutics (NASDAQ:MSTX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. Equities research analysts forecast that Mast Therapeutics will post ($0.19) EPS for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.
Mast Therapeutics Company Profile